Biogen Tau Therapy Data, SSRI Tapering Guidance & FDA Wearable Injector: Week in Review

References

1. 1.Keshavan, M. (2026, July 13). All eyes on data on Biogen's tau therapy. STAT News. https://www.statnews.com/2026/07/13/biotech-news-all-eyes-on-biogen-tau-therapy-data/
2. 2.Iqbal, K., Liu, F., & Gong, C. X. (2016). Tau and neurodegenerative disease: The story so far. Nature Reviews Neurology, 12(1), 15–27. https://doi.org/10.1038/nrneurol.2015.225
3. 3.Cummings, J., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., & Cheng, F. (2024). Alzheimer's disease drug development pipeline: 2024. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 10(2), e12465. https://doi.org/10.1002/trc2.12465
4. 4.Horowitz, M. A., & Taylor, D. (2019). Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry, 6(6), 538–546. https://doi.org/10.1016/S2215-0366(19)30032-X
5. 5.Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., & Bülow, L. (2013). Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): An open-label randomised study. The Lancet Oncology, 14(10), 962–970. https://doi.org/10.1016/S1470-2045(13)70383-8
6. 6.Prasad, V., Jorgenson, J., Ioannidis, J. P. A., & Cifu, A. (2013). Observational studies often make clinical practice recommendations: An empirical evaluation of authors' attitudes. Journal of Clinical Epidemiology, 66(4), 361–366. https://doi.org/10.1016/j.jclinepi.2012.09.015
7. 7.Alzheimer's Disease International. (2023). World Alzheimer Report 2023: Reducing dementia risk. Alzheimer's Disease International. https://www.alzint.org/resource/world-alzheimer-report-2023/
8. 8.Scott, I. A., Hilmer, S. N., Reeve, E., Potter, K., Le Couteur, D., Rigby, D., & Martin, J. H. (2015). Reducing inappropriate polypharmacy: The process of deprescribing. JAMA Internal Medicine, 175(5), 827–834. https://doi.org/10.1001/jamainternmed.2015.0324